[18F] FDG PET/CT can improve the diagnostic accuracy for aortic endograft infection

Acta Cardiol. 2022 Jul;77(5):399-407. doi: 10.1080/00015385.2021.1949105. Epub 2021 Oct 7.

Abstract

Purpose: Aortic endograft infection (EI) can result in potentially life-threatening vascular complications. Unfortunately, it is difficult to obtain a correct diagnosis at an early stage in many patients. This report aims at validating the use of [18F] FDG PET/CT imaging for suspected endograft infections in a prospectively collected cohort of patients treated with EVAR and TEVAR.

Materials and methods: During a 14-year period, 366 patients required aortic stent graft. All procedures were performed electively, except for one patient. Among these 366 patients, eleven patients (3%) were suspected to have aortic EI. Contrast-enhanced CT and FDG PET/CT were performed in all 11 patients. Medical charts and imaging were analysed for these 11 cases, with initial positive CT.

Results: The final diagnosis of EI was established in seven (1,9%) based on clinical features, laboratory investigations and a significant [18F] FDG uptake in the aortic graft as well as the aortic wall. The median time from the initial EVAR/TEVAR to diagnosed infection was 180 days. During follow-up, the seven patients had a second PET/CT that was compared with the initial evaluation, decreased uptake was correlated with clinical improvement.

Conclusions: Contemporary diagnostic imaging for a potentially lethal endograft infection lacks precision, this observational study illustrates the potential clinical value of [18F] FDG PET/CT in the management of aortic EI. [18F] FDG PET/CT constitutes an imaging modality able to confirm the diagnosis, monitor disease progression as well as the effect of pharmaceutical treatment and detect relapse.

Keywords: Aortic graft infection; abdominal aortic aneurysm; endograft; endovascular; imaging; positron emission tomography.

Publication types

  • Observational Study

MeSH terms

  • Aorta
  • Fluorodeoxyglucose F18* / pharmacology
  • Humans
  • Positron Emission Tomography Computed Tomography* / methods
  • Positron-Emission Tomography
  • Radiopharmaceuticals / pharmacology
  • Stents / adverse effects

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18